Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-210 vs Intravesical Chemotherapy in Intermediate-risk NMIBC with FGFR Alterations
NCT06319820Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease Free Survival. Started Apr 2024; status: recruiting.
02
Drugs
erdafitinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06319820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319820.